

---

# Prioritization, Costing and Resource Mobilization for NCCPs

**Dr. Mary Nyangasi**

**Technical Officer, Cancer**

**World Health Organization**



---

Dr. Mary Nyangasi

Technical Officer, Cancer

World Health Organization



# Good practices for NCCP planning

- Government stewardship & ownership: for leadership, ownership, accountability, resource allocation
- Alignment with relevant global and regional initiatives
- Aligns with national health strategy , overall govt agenda and other health programs
- Multisectoral and multistakeholder engagement
- Equity, human rights, pt-centred



# Government-led process, with stakeholder engagement and participation



## PHASE 1 – Planning and preparation

- Establishing a core organizing team
- Developing a costed roadmap
- Confirming and mobilizing resources

## PHASE 2 – Conducting the situation analysis

- Review of epidemiology and determinants of TB<sub>a</sub>
- TB programme review<sub>b</sub>
- Data and evidence consolidation
- Synthesis by stakeholders

## PHASE 3 – Formulating goal(s), objectives, interventions and activities

- Formulating goal(s) and objectives
- Identifying priority interventions
- Determining epidemiological (coverage) targets
- Formulating activities and subactivities
- Contingency planning

## PHASE 4 – Developing the metrics and activities for monitoring, evaluation and review

- Formulating indicators and targets for activities and subactivities
- Outlining activities for monitoring, evaluation

## PHASE 5 – Costing

- Producing cost estimates
- Identifying projected funding and sources

## PHASE 6 – Consensus and endorsement, dissemination and resource mobilization

- Consensus and endorsement
- Dissemination and advocacy
- Resource mobilization

9–12 months




---


## Prioritization

- During planning, goals and objectives are identified to define the priority interventions and target setting (**prioritization**). The M&E framework is also defined at this stage.
- The process of making choices between different options to address the most important health needs given scarce resources.
- Should be evidence-based, unbiased, impartial and should be seen as fair by all affected parties
- Priorities reflect a compromise among stakeholders
- Societal values and goals should guide

## The Phases of a Program Management Cycle




# Universal health coverage and cancer




Ideally we would like to cover everyone with effective cancer services

But we have limited resources.  
So how do we proceed?



# The 3Ds of decision making



Systematic process, institutionalized with legal basis

# Priority-setting policy dialogue

*Status quo:* Lack of prioritization

Domain	Example	Process & Outcome
Cancer control plan	<p>70% NCCPs include breast cancer screening  <b>YET....</b> Feasible &amp; cost-effective in <b>&lt;20%</b></p>	<p>Political but should be based on:            Data → Dialogue → Decision-making</p>
Benefit package (UHC)	<p><b>&lt;20%</b> of packages include palliative care  <b>YET...40+%</b> of packages in LIC cover screening</p>	<p>  <b>Cancer control doesn't need to be expensive...</b>  <b>But, it does need to be prioritized</b>  <b>Basic package implementable for \$US 5-10 per capita</b></p>
Treatment standards	<p><b>20%</b> of nEMLs include bevacizumab            but <b>not asparaginase</b></p>	

# Priority-setting policy dialogue


*Status quo:* Lack of prioritization

Domain

Example

Process & Outcome

Political but should be based on:  
Data → Dialogue → Decision-making



(1) Define interventions

(2) Focus on scale-up

(3) Evaluate system readiness



50% NCCPs include breast cancer screening  
Feasible & cost-effective in <20%

# (1) Defining priority interventions

Best investment must reach scale & achieve value for money

SEVENTIETH WORLD HEALTH ASSEMBLY  
Agenda item 15.6  
Cancer prevention and control in the context of an integrated approach

WHA70.12  
31 May 2017

Recalling also United Nations General Assembly resolution Declaration of the High-level Meeting of the General Assembly on Non-communicable Diseases, which includes a road map for State and Government to address cancer and other non-communicable diseases, including those related to addressing cancer;


Recalling further resolution WHA66.10 (2013) on prevention and control of non-communicable diseases 2013-2020, in which Member States can realize the commitments they made in the Meeting of the General Assembly on the Prevention and Control of Non-communicable Diseases, including those related to addressing cancer;

Recalling in addition United Nations General Assembly Outcome document of the high-level meeting of the General Assembly and assessment of the progress achieved in the prevention and control of non-communicable diseases, which sets out the continued and increased commitments that are essential for Member States to address cancer and other non-communicable diseases, including four time-bound national commitments to the Declaration of the High-level Meeting of the General Assembly on Non-communicable Diseases, in accordance with the technical note published in 2015;

Mindful of the existing monitoring tool that WHO is using to track non-communicable diseases, in accordance with the technical note published in 2015, and in line with the WHO Framework Convention on Tobacco Control; and in line with Sustainable Development Goal 3 (Ensure healthy lives and promote well-being for all at all ages), specifically Target 3.8 on achieving universal health coverage, and in line with the efforts made by Member States<sup>2</sup> and international partners in the context of the Sustainable Development Goals of the 2030 Agenda for Sustainable Development, to reduce, by 2030, premature mortality from noncommunicable diseases by one-third, on the basis of the strategy and plan of action on public health, innovation and research, and in line with the efforts made by Member States to the full use of the flexibility provisions of the Intellectual Property Rights (TRIPS) to promote the development of new health products, and in line with the efforts made by Member States to the full use of the flexibility provisions of the Intellectual Property Rights (TRIPS) to promote the development of new health products, and in line with the efforts made by Member States to the full use of the flexibility provisions of the Intellectual Property Rights (TRIPS) to promote the development of new health products;

Recalling resolution WHA58.22 (2005) on cancer prevention and control;

Topic	Topic 1	Topic 2	Topic 3
Prevention	WHO Framework	WHO Framework	WHO Framework
Control	WHO Framework	WHO Framework	WHO Framework
Partners	WHO Framework	WHO Framework	WHO Framework
Priority	WHO Framework	WHO Framework	WHO Framework
Impact	WHO Framework	WHO Framework	WHO Framework
Enabling Strategy	WHO Framework	WHO Framework	WHO Framework
Measurement	WHO Framework	WHO Framework	WHO Framework
Partnership	WHO Framework	WHO Framework	WHO Framework



OP1

- Develop **resource-stratified tool kits** to establish and implement comprehensive programmes... **leveraging work of other organizations**

✓

OP2

- Collect, synthesize and disseminate evidence on the **most cost-effective interventions**...and to make an **investment case** for cancer

✓

OP3

- Strengthen the capacity of the Secretariat to support implementation of cost-effective interventions and **country-adapted models**...

## 1) Priority interventions defined as "buys"

# Country Example

WHO, IARC, IAEA prioritization




## 1<sup>st</sup> Feasibility assessment, scenarios and priorities

Management Policies	
Cancer guidelines	yes
Cancer guidelines incl drug-specific protocols	yes
Cancer guidelines (utilized in >50% facilities)	yes
Cancer guideline (last updated)	2019
Cancer guidelines (include referral criteria)	yes
Breast cancer early detection pgm/guidelines	yes
Cervical cancer early detection pgm/guidelines	yes
Colon cancer early detection pgm/guidelines	no
Childhood cancer early detection pgm/guidelines	no
Breast cancer defined referral	
Cervical cancer defined referral	
Colon cancer defined referral	
Childhood cancer defined referral	no
Breast cancer screening pgm	yes
Breast cancer screening pgm (type)	opportunistic
Breast cancer screening pgm (method)	clinical breast exam
Breast cancer screening pgm (coverage)	>50% and <70%
Breast cancer screening pgm (target age start)	15
Breast cancer screening pgm (target age end)	60
Breast screening test performance (sens)	
Breast screening test performance (sens)	
Cervical cancer screening pgm	yes
Cervical cancer screening pgm (type)	opportunistic
Cervical cancer screening pgm (method)	visual inspection
Cervical cancer screening pgm (coverage)	>50% and <70%
Cervical cancer screening (STEPS)	
Cervical cancer screening pgm (target age start)	15
Cervical cancer screening pgm (target age end)	60

**Goal:** ↑coverage by 1% per yr, focusing on women + children

## 2<sup>nd</sup> Health system planning & capacity



### EQUIPMENT

- Pathology
- Radiology
- Cancer Diagnosis
- Prostate Cancer
- Diagnosis
- Palliative care



### CONSUMABLES

- Records
- Endoscopy
- Radiology and Nuclear
- Medicine Treatment
- Palliative care.




### TRAINING

- In service training
- Quality control programs
- Early Diagnosis Policies
- Service Organization
- Others


**Capacity:** workforce as bottleneck to reach goal

## 3<sup>rd</sup> Generate business model




— Baseline (no further investment)  
— Scale-up (1% ↑ coverage / year)

**Investment:** ↑\$US 0.30 to save 100 lives per year (50% <60yo)




- Matching tools to country-based stakeholder needs



**Justifications:**

- (1) **<30%** MBP include essential cancer services
- (2) **9%** NCCP are costed
- (3) **<5%** ODA allocated to cancer
- (4) **>70%** cancer programs w/ insufficient HWF


- Matching tools to country-based stakeholder needs




**Justifications:**


- (1) **<30%** HBP include essential cancer services
- (2) **9%** NCCP are costed
- (3) **<5%** ODA allocated to cancer
- (4) **>70%** cancer programs w/ insufficient HWF

- Matching tools to country-based stakeholder needs



# WHO-IARC Costing Tool structure






## Data inputs

- ✓ **Disease burden**
  - ✓ By cancer, by 5yr age cohort
  - ✓ Stage distribution
- ✓ **Current outcomes**
  - ✓ Survival by stage by cancer
  - ✓ Treatment delays, abandonment
- ✓ **Health system capacities**
  - ✓ Workforce by occupation
  - ✓ Technology availability (by facility)
  - ✓ Expenditure on cancer (including meds)
  - ✓ Referral to private sector or globally
  - ✓ MoH capabilities & governance
- ➔ **Service coverage** (by cancer) (patients per facility)

## SELECTING PACKAGE & SCALE-UP SCENARIOS



## OUTPUTS

### Health Impact

- Lives saved
- Cases averted
- DALYs / HLYg

### Health System Requirements

- Facilities
- Health workforce
- Capital & recurrent costs
- Programmatic costs

### Scale-Up


- Costs
- Coverage rates

### Total Costs

- Costs
- *Financing approaches*

# Sources of funding

*Who is providing the financing?*



- (1) Prefinancing:**
  - (a) Mandatory** (general govern't expenditure)
  - (b) Voluntary** (eg, private insurer, community-based)
- (2) Out-of-pocket payment (OOP)**


- (1) Loans for national/international banks**
- (2) Grants from donors, development assistance**
- (3) In-kind support (minor)**

e.g. Innovative financing instruments


# Share of health spending

## *Burden of OOP*


Low income




Lower middle income




Upper middle income



High income



# Financial burden of cancer to households



Financial catastrophe due to the costs of cancer treatment


- In many countries, families bear cost of cancer care
- Large out-of-pocket spending puts a heavy burden on families, especially poor
- **50-90% risk** of impoverishment due to catastrophic health spending → generational impoverishment.
- **30-80% risk** of abandonment

# Development assistance (grants)

Not coming, not enough

## Flows of global health financing

Total for 2019: \$41 billion in 2019 US dollars



**In 2019, \$730 million DAH for NCDs**

# Making cancer care available

Health financing system



How do we spend it? (*economic factors*)

- To promote equitable, resource use?

• **So, where do we go from here?**



Where does the money come from? (*financial factors*)

- To ensure sufficient and sustainable financing?

---

## Actions that facilitate implementation of national strategic plans

The main actions that facilitate the implementation of NSPs are:


- 1. Supportive supervision-** a facilitative approach that enables mentorship, joint problem solving and communication between the mentee and supervisor
- 2. Monitoring**
- 3. Evaluation**
- 4. Reviews** (quarterly, annual, mid-term of end term)

# Guiding principles: *governance, capacity building & accountability*



Strategies for impact

## Foundations for success



## Threats to impact

	Before plan implementation*	After plan implementation†	p value‡
<b>Absolute change in prevalence of smoking in men, 2000–15<sup>24</sup></b>			
All countries (n=59)	-2.1% (4.2)	-1.4% (4.0)	0.17
Tobacco strategy specified (n=53)	-2.0% (4.4)	-1.2% (4.2)	0.07
Tobacco strategy not specified (n=6)	-3.8% (1.4)	-3.3% (1.2)	0.10
<b>Availability of breast cancer screening programme, 2010–15<sup>8</sup></b>			
All countries (n=48)	42 (88%)	36 (75%)	0.10
Breast cancer screening strategy specified (n=43)	38 (88%)	34 (79%)	0.70
Breast cancer screening strategy not specified (n=5)	4 (80%)	2 (40%)	0.07
<b>New radiotherapy units acquired per year, 1965–2018<sup>25</sup></b>			
All countries (n=60)	1.9 (2.9)	3.7 (4.8)	0.01
Radiotherapy mentioned (n=33)	2.4 (3.7)	4.9 (5.9)	0.01

## Effective cancer strategy requires

- ✓ Resources to operationalize
- ✓ MoH focal point
- ✓ Investment in infrastructure & workforce
- ✓ **Robust M&E mechanism with accountability**

---

A well-structured evidence-based, costed NCCP with clearly defined goals, targets and clear monitoring and evaluation framework is in itself a resource mobilization tool.

**Why? Funding gap identified during costing exercise is highlighted during the dissemination exercise and can be used to reach out to funding partners.**

# Conclusions

Where to go from here

✓ **Costing is essential.**

Approach should focus on **process**, not outcome: **ownership is important**

- Priority-setting, stakeholder-led “**dialogues**” foundational to success, founded on “**data**”
- “Decision”: **align timing** with broader policy discussions (eg, national health plans)

✓ Priority setting **can be** done by cancer type and intervention type

✓ WHO – working with IARC, IAEA, ICCP and others – have tools to support

- **Data-driven** decisions are best, based on **health systems investments**

✓ Financing cancer control: requires **multi-dimensional dialogues**

Based on need and financing streams (eg, governmental agencies, development banks)

Must focus on **domestic financing** for sustainability

Investment cases must show the **full social and economic impact of cancer**

---

# Thank you

[nyangasim@who.int](mailto:nyangasim@who.int)



S.NO.	Name of technical resource	Link to resources	What year was this resource last updated?
1	Cancer control : knowledge into action : WHO guide for effective programmes ; module 1. Planning	<a href="https://www.who.int/publications/i/item/9241546999">https://www.who.int/publications/i/item/9241546999</a>	2006
2	Cancer control: Prevention	<a href="https://www.who.int/publications/i/item/9241547111">https://www.who.int/publications/i/item/9241547111</a>	2007
3	Cancer control: Early detection	<a href="https://www.who.int/publications/i/item/9789241547338">https://www.who.int/publications/i/item/9789241547338</a>	2006
4	Cancer control: Diagnosis and treatment	<a href="https://www.who.int/publications/i/item/9241547406">https://www.who.int/publications/i/item/9241547406</a>	2011
5	Cancer control: Palliative Care	<a href="https://www.who.int/publications/i/item/9241547345">https://www.who.int/publications/i/item/9241547345</a>	2014
6	Cancer control: Policy and advocacy	<a href="https://www.who.int/publications/i/item/9241547529">https://www.who.int/publications/i/item/9241547529</a>	2008
7	Global breast cancer initiative implementation framework: assessing, strengthening and scaling up of services for the early detection and management of breast cancer: executive summary	<a href="https://www.who.int/publications/i/item/9789240067134">https://www.who.int/publications/i/item/9789240067134</a>	2023
8	Global breast cancer initiative implementation framework: assessing, strengthening and scaling up of services for the early detection and management of breast cancer	<a href="https://www.who.int/publications/i/item/9789240065987">https://www.who.int/publications/i/item/9789240065987</a>	2023
9	National Cancer Control Programmes	<a href="https://www.who.int/publications/i/item/national-cancer-control-programmes">https://www.who.int/publications/i/item/national-cancer-control-programmes</a>	2002
10	WHO Guide to cancer early diagnosis	<a href="https://www.who.int/publications/i/item/9789241511940">https://www.who.int/publications/i/item/9789241511940</a>	2017
11	Guide for establishing a pathology laboratory in the context of cancer control	<a href="https://www.who.int/publications/i/item/guide-for-establishing-a-pathology-laboratory-in-the-context-of-cancer-control">https://www.who.int/publications/i/item/guide-for-establishing-a-pathology-laboratory-in-the-context-of-cancer-control</a>	2020
13	Roadmap towards a National Cancer Control Programme	<a href="https://www.iaea.org/sites/default/files/19/10/milestones-document-2019.pdf">https://www.iaea.org/sites/default/files/19/10/milestones-document-2019.pdf</a>	2019
14	National cancer control programmes core capacity self-assessment tool	<a href="https://www.who.int/publications/i/item/national-cancer-control-programmes-core-capacity-self-assessment-tool">https://www.who.int/publications/i/item/national-cancer-control-programmes-core-capacity-self-assessment-tool</a>	2011